EA201892010A1 - Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию - Google Patents

Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Info

Publication number
EA201892010A1
EA201892010A1 EA201892010A EA201892010A EA201892010A1 EA 201892010 A1 EA201892010 A1 EA 201892010A1 EA 201892010 A EA201892010 A EA 201892010A EA 201892010 A EA201892010 A EA 201892010A EA 201892010 A1 EA201892010 A1 EA 201892010A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
locuses
enhanced expression
application
Prior art date
Application number
EA201892010A
Other languages
English (en)
Inventor
Роберт Бабб
Дарья Бураков
Ганг Чен
Джеймс П. Фандл
Ю Чжао
Original Assignee
Регенерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Регенерон Фармасьютикалз, Инк. filed Critical Регенерон Фармасьютикалз, Инк.
Publication of EA201892010A1 publication Critical patent/EA201892010A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к сайт-специфической интеграции и экспрессии рекомбинантных белков в эукариотических клетках. В частности, настоящее изобретение включает композиции и способы для обеспечения улучшенной экспрессии антигенсвязывающих белков, включая моноспецифические и биспецифические антитела, в эукариотических клетках, в частности, в линиях клеток китайского хомячка (Cricetulus griseus), посредством применения нескольких локусов, обеспечивающих повышенную экспрессию.
EA201892010A 2016-04-20 2017-04-20 Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию EA201892010A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325400P 2016-04-20 2016-04-20
PCT/US2017/028555 WO2017184832A1 (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of expression-enhancing loci

Publications (1)

Publication Number Publication Date
EA201892010A1 true EA201892010A1 (ru) 2019-03-29

Family

ID=58701851

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892010A EA201892010A1 (ru) 2016-04-20 2017-04-20 Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию

Country Status (15)

Country Link
US (2) US11512144B2 (ru)
EP (1) EP3445781A1 (ru)
JP (3) JP7096770B2 (ru)
KR (2) KR20230098361A (ru)
CN (2) CN116515757A (ru)
AR (1) AR109451A1 (ru)
AU (1) AU2017253241A1 (ru)
BR (1) BR112018071283A2 (ru)
CA (1) CA3015389A1 (ru)
EA (1) EA201892010A1 (ru)
IL (1) IL262266A (ru)
MX (1) MX2018012868A (ru)
SG (2) SG10202010155YA (ru)
TW (1) TWI827531B (ru)
WO (1) WO2017184832A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017253241A1 (en) * 2016-04-20 2018-09-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
CA3083579A1 (en) * 2017-12-22 2019-06-27 Genentech, Inc. Targeted integration of nucleic acids
KR20210107057A (ko) * 2018-12-21 2021-08-31 제넨테크, 인크. 핵산의 표적화 통합
CA3134705A1 (en) * 2019-04-02 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
AU2020308002A1 (en) 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids
US20230304062A1 (en) 2021-10-18 2023-09-28 Regeneron Pharmaceuticals, Inc. Controlled transcription of polynucleotides
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
WO2023122246A1 (en) * 2021-12-22 2023-06-29 Genentech, Inc. Multi-vector recombinase mediated cassette exchange
WO2023238949A1 (ja) * 2022-06-10 2023-12-14 富士フイルム株式会社 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
CA2485939C (en) 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
CA2504595A1 (en) 2002-11-14 2004-06-03 Lynne Krummen Intron fusion construct and method of using for selecting high-expressing production cell lines
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
US20100105042A1 (en) 2006-12-21 2010-04-29 Smithkline Beecham Corporation Novel methods
WO2008089396A1 (en) 2007-01-19 2008-07-24 Invitrogen Corporation Compositions and methods for genetic manipulation and monitoring of cell lines
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
EP2150617B1 (en) * 2007-06-04 2014-10-22 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8409838B2 (en) * 2009-06-02 2013-04-02 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
EP3916011A1 (en) 2009-06-26 2021-12-01 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US20120231449A1 (en) 2009-09-18 2012-09-13 Selexis S.A. Products and methods for enhanced transgene expression and processing
KR102152109B1 (ko) 2010-04-20 2020-09-07 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
TW201823460A (zh) 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
EP2711428A1 (en) * 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TW202206465A (zh) 2012-11-14 2022-02-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (zh) 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
WO2016064999A1 (en) 2014-10-23 2016-04-28 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
EA201890785A1 (ru) 2015-09-23 2018-10-31 Ридженерон Фармасьютикалз, Инк. Оптимизированные биспецифические анти-cd3 антитела и их применение
AU2017253241A1 (en) * 2016-04-20 2018-09-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci

Also Published As

Publication number Publication date
KR102547738B1 (ko) 2023-06-26
TW201803986A (zh) 2018-02-01
EP3445781A1 (en) 2019-02-27
WO2017184832A1 (en) 2017-10-26
CA3015389A1 (en) 2017-10-26
JP2019515666A (ja) 2019-06-13
CN109195986B (zh) 2023-01-03
US20230130799A1 (en) 2023-04-27
BR112018071283A2 (pt) 2019-02-12
AR109451A1 (es) 2018-12-12
JP2024023449A (ja) 2024-02-21
MX2018012868A (es) 2019-03-11
AU2017253241A1 (en) 2018-09-20
US20190233544A1 (en) 2019-08-01
CN116515757A (zh) 2023-08-01
KR20180134893A (ko) 2018-12-19
TWI827531B (zh) 2024-01-01
US11512144B2 (en) 2022-11-29
JP2021164479A (ja) 2021-10-14
IL262266A (en) 2018-11-29
SG11201807885PA (en) 2018-10-30
JP7096770B2 (ja) 2022-07-06
KR20230098361A (ko) 2023-07-03
SG10202010155YA (en) 2020-11-27
CN109195986A (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
EA201892010A1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
EA201892137A1 (ru) Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
BR112019007288A2 (pt) proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EA201892693A1 (ru) Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
AR121002A2 (es) Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica
AR103867A1 (es) Anticuerpos contra inmunoglobulina y dominio 3 que contiene mucina de células t (anti-tim3), útiles como agentes terapéuticos
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2020010241A (es) Composiciones de inmunoterapia celular y usos de las mismas.
EA201591407A1 (ru) Антитела, содержащие химерные константные домены
BR112015022260A2 (pt) anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico
MX2016008472A (es) Anticuero monoclonal neutralizador de anti-il-33-humana.
MX2018004531A (es) Proteinas de union a antigeno que activan el receptor de leptina.
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201792442A1 (ru) Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение
AR115963A1 (es) Anticuerpos anti-il1rap y métodos de uso de estos
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
EA201991912A1 (ru) Составы, содержащие pd-1-связывающие белки, и способы их получения
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина